Theravance Biopharma (TBPH) executive compensation, 2026 proxy

Rick E Winningham, Chief Executive Officer, was paid $1.5M in 2025, down 63% from $4M the year before.

Filed
April 28, 2026
Annual meeting
June 12, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.5M-63% vs prior year
CEO Target Bonus
60%Percentage of annual base salary
YUPELRI Net Sales Growth
12%Increase compared to 2024
Bonus Pool Funding
66.7%Percentage of target

How Winningham was paid

$1.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary71%Non-equity incentive28%All other compensation0%

Named executive officers

ExecutiveTotal
Rick E WinninghamChief Executive Officer$1,472,019
Rhonda F. FarnumChief Business Officer and Senior Vice President, Commercial & Medical Affairs$1,384,192
Aine MillerSenior Vice President, Development and Head of Ireland Office$1,448,573

What changed and why

  • $1.5MChief executive officer total compensation decreased to $1,472,019 in 2025 from $3,995,931 in 2024.
  • $1MChief executive officer base salary remained unchanged for the fourth consecutive year at $1,047,431.
  • Chief executive officer forgone equity awards resulted in zero stock awards granted for 2025.
  • 66.7%Annual cash bonus pool was funded at 66.7% of target based on 2025 corporate performance goals.
  • $266.6MTotal YUPELRI net sales increased by 12% to $266.6 million in 2025 compared to 2024.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.